H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...
While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical ...
today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...
proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in ...
The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at approximately $16.7 ...
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...